UnitedHealth Group (UNH) Given New $240.00 Price Target at Oppenheimer

UnitedHealth Group (NYSE:UNH) had its price target hoisted by Oppenheimer from $260.00 to $240.00 in a research note released on Wednesday morning. The firm currently has an outperform rating on the healthcare conglomerate’s stock. Oppenheimer also issued estimates for UnitedHealth Group’s Q2 2018 earnings at $2.98 EPS, Q1 2019 earnings at $2.88 EPS, Q2 2019 earnings at $3.05 EPS, Q3 2019 earnings at $3.26 EPS, Q4 2019 earnings at $3.15 EPS and FY2019 earnings at $12.33 EPS.

Several other equities research analysts have also recently weighed in on the stock. Cantor Fitzgerald increased their target price on shares of UnitedHealth Group to $225.00 and gave the company an overweight rating in a research note on Wednesday, October 18th. Credit Suisse Group initiated coverage on shares of UnitedHealth Group in a research note on Thursday, November 2nd. They issued an outperform rating and a $233.00 target price for the company. Wells Fargo & Co reiterated an outperform rating and issued a $245.00 target price (up previously from $230.00) on shares of UnitedHealth Group in a research note on Wednesday, November 29th. ValuEngine cut shares of UnitedHealth Group from a buy rating to a hold rating in a research note on Thursday, December 7th. Finally, Royal Bank of Canada increased their target price on shares of UnitedHealth Group to $244.00 and gave the company an outperform rating in a research note on Wednesday, November 29th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $241.30.

UnitedHealth Group (UNH) traded up $4.73 during midday trading on Wednesday, hitting $243.16. 6,233,080 shares of the company traded hands, compared to its average volume of 2,990,000. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 0.52. UnitedHealth Group has a twelve month low of $156.09 and a twelve month high of $243.90. The company has a market capitalization of $235,100.00, a PE ratio of 22.70, a PEG ratio of 1.48 and a beta of 0.66.

UnitedHealth Group (NYSE:UNH) last released its earnings results on Tuesday, January 16th. The healthcare conglomerate reported $2.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.09. UnitedHealth Group had a net margin of 5.25% and a return on equity of 21.79%. The business had revenue of $52.06 billion during the quarter, compared to analysts’ expectations of $51.57 billion. During the same quarter last year, the company earned $2.11 earnings per share. The firm’s revenue was up 9.5% on a year-over-year basis. sell-side analysts predict that UnitedHealth Group will post 11.66 earnings per share for the current year.

In other news, CEO Larry C. Renfro sold 22,598 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $221.75, for a total transaction of $5,011,106.50. Following the completion of the sale, the chief executive officer now owns 195,314 shares of the company’s stock, valued at $43,310,879.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Kenneth Irwin Shine sold 457 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $211.03, for a total transaction of $96,440.71. The disclosure for this sale can be found here. Insiders sold 33,655 shares of company stock valued at $7,469,083 in the last three months. Company insiders own 0.89% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marshall Wace LLP increased its holdings in shares of UnitedHealth Group by 441.4% during the second quarter. Marshall Wace LLP now owns 13,935 shares of the healthcare conglomerate’s stock worth $2,578,000 after buying an additional 11,361 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of UnitedHealth Group by 16.9% during the second quarter. American Century Companies Inc. now owns 4,703,113 shares of the healthcare conglomerate’s stock worth $872,051,000 after buying an additional 681,111 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of UnitedHealth Group by 5.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 3,656,975 shares of the healthcare conglomerate’s stock worth $678,077,000 after buying an additional 183,401 shares in the last quarter. Essex Financial Services Inc. increased its holdings in shares of UnitedHealth Group by 12.3% during the second quarter. Essex Financial Services Inc. now owns 8,846 shares of the healthcare conglomerate’s stock worth $1,640,000 after buying an additional 967 shares in the last quarter. Finally, Bainco International Investors increased its holdings in shares of UnitedHealth Group by 5.4% in the third quarter. Bainco International Investors now owns 82,676 shares of the healthcare conglomerate’s stock valued at $16,192,000 after purchasing an additional 4,202 shares in the last quarter. 86.09% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/19/unitedhealth-group-unh-given-new-240-00-price-target-at-oppenheimer.html.

About UnitedHealth Group

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply